In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. Tokyo-headquartered Astellas has developed a strong portfolio in urology, oncology and immunology, most recently with US FDA approval for Vyloy (zolbetuximab), a key addition to its cancer treatments.


The Pharma Letter Podcast — Episode 30 — Japanese pharma in the UK | Pharmaceutical | The Pharmaletter | The Pharmaletter

The Pharma Letter Podcast — Episode 30 — Japanese pharma in the UK

column-header-date-desktop-only-1

column-header-logo-1

column-header-secondary-menu-desktop-only-1

row-header-1

row-header-and-main-menu-1

row-menu-container-1

code-sticky-header-1

row-header-background-1

banner-leaderboard

row-leaderboard

row-leaderboard-banner-bg-container

breadcrumb

row-breadcrumb

datasummary-page-title

row-title-row

row-row-category-date-container

row-category-date

column-main

column-sidebar

row-main-section

card-more-features-in-category

row-other-related

code-banner-spacer-3

banner-billboard-bottom

row-billboard-bottom

row-page

footer-first-column-2

footer-second-column-2

footer-third-column-2

row-footer-2

row-footer-container-2

textblock-copyright

row-copyright

backtotop-1

gtm-user-all-block

structured-data-component-header-auto

The Pharma Letter Podcast — Episode 30 — Japanese pharma in the UK

More on this story...

Today's issue

Company Spotlight

More Features in Pharmaceutical